Elicio Therapeutics Inc. logo

Elicio Therapeutics Inc.(ELTX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.5
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ELTX

11/13/2026: ELTX (1-star) is currently NOT-A-BUY. Pass it for now.

Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on advancing novel immunotherapies and therapeutic cancer vaccines using its proprietary Amphiphile delivery platform. The company's primary investment appeal centers on its lead candidate, ELI-002 7P, which targets prevalent mutant KRAS solid tumors such as pancreatic and colorectal cancer. Key strengths include innovative lymph node-targeting science and an active clinical pipeline addressing high unmet medical needs. However, the company faces substantial risks, including ongoing operating losses, a tight cash runway, frequent equity dilution, and intense competition in precision oncology. This stock best suits high-risk growth investors willing to tolerate high volatility around clinical data milestones while monitoring capital raises and trial readouts.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers high-growth clinical potential in cancer immunotherapy, balanced against early-stage pipeline risks.
Momentum investorStrong fit while signal remains positiveSuitable for momentum strategies only during windows of positive clinical data readouts or high-volume market activity.
Value investorWeak fitLacks commercial revenue, earnings, or traditional valuation metrics.
Dividend investorWeak fitDoes not pay dividends and consumes capital for clinical development.
Low-risk investorWeak fitExhibits high clinical binary risk, stock price volatility, and frequent equity dilution.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks experience sharp price fluctuations based on trial updates and market sentiment.
Valuation riskHighValuation is speculative and heavily tied to clinical success rather than current financial earnings.
Competition risk (oncology immunotherapy competition)HighThe competitive landscape for KRAS-targeted therapies includes heavily capitalized pharmaceutical and biotech rivals.
Business qualityMediumThe company possesses promising scientific technology, but lacks commercial validation and steady revenue streams.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess relies heavily on flawless clinical trial execution, regulatory approvals, and securing ongoing funding.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 42.46M USD
Price to earnings Ratio -
1Y Target Price 13
Price to earnings Ratio -
1Y Target Price 13
Volume (30-day avg) 302.5K shares
Beta 2
52 Weeks Range 1.25 - 16.00
Updated Date 11/15/2026
52 Weeks Range 1.25 - 16.00
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.81

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -42.85%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ELTX receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
ELTX has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+23.8%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
ELTX's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is ELTX's strongest growth driver at +23.8% FY2025 versus FY2024 (solid, 4 stars). By comparison, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 22.6% and approximately 75.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 25.86% supports management-shareholder alignment.

Top 5 Institutional Investors

Shah Capital Management 4.42%
Knoll Capital Management LP 4.28%
BlackRock Inc 2.71%
Vanguard Capital Management, LLC 2.02%
Geode Capital Management, LLC 1.10%

Unit Economics (Per $1K Revenue)

★★★★★
ELTX generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
ELTX has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Therapeutics and CollaborationsFuture commercial product sales, potential milestone payments, and research licensing fees from its immunotherapy pipeline.The company currently generates no commercial revenue and relies on equity financing while advancing its clinical candidates.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 25.55M
Price to Sales(TTM) -
Enterprise Value 25.55M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -2.61
Shares Outstanding 28.31M
Shares Floating 21.23M
Shares Outstanding 28.31M
Shares Floating 21.23M
Percent Insiders 25.86
Percent Institutions 22.6

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.